Ibritumomab tiuxetan

Drug Profile

Ibritumomab tiuxetan

Alternative Names: 111In-ibritumomab tiuxetan; BAY86-5128; IDEC-129; IDEC-In2B8; IDEC-Y2B8; Indium-111 Ibritumomab tiuxetan; Monoclonal antibody IDEC-Y2B8; SH-L-749; Yttrium-90 ibritumomab tiuxetan; Zevalin; Zevamab

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Bayer Yakuhin; Biogen; CASI Pharmaceuticals; Dana-Farber Cancer Institute; Schering Korea; Spectrum Pharmaceuticals; Tufts-New England Medical Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action CD20 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Discontinued Diffuse large B cell lymphoma; MALT lymphoma; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 11 Jul 2017 Discontinued - Phase-II for Diffuse large B cell lymphoma (Combination therapy, Late-stage disease, Metastatic disease) in Thailand (IV)
  • 11 Jul 2017 Discontinued - Phase-II for MALT lymphoma (Combination therapy, First-line therapy) in USA (IV)
  • 11 Jul 2017 Discontinued - Phase-II for Mantle cell lymphoma (Combination therapy, First-line therapy, Recurrent, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top